Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8 + memory T cells

American Journal of Transplantation

Volumn 12, Issue 1, 2012, Pages 69-80

  Kitchens, W H ^a   Haridas, D ^a   Wagener, M E ^a   Song, M ^a   Kirk, A D ^a   Larsen, C P ^a   Ford, M L ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Costimulatory blockade; integrins; LFA 1; memory T cells; VLA 4

Indexed keywords

INTEGRIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; COSTIMULATORY BLOCKADE; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOLOGIC MEMORY; INTEGRINS; MALE; MICE; MICE, INBRED C57BL;

EID: 84855943600     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03762.x     Document Type: Article

References (66)

1. Weaver T, Charafeddine A, Kirk A,. Costimulation blockade: Towards clinical application. Front Biosci 2008; 13: 2120-2139. (Pubitemid 351589240)
2. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD,. A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6 (5 Pt 1): 876-883. (Pubitemid 44356637)
3. Vadivel N, Trikudanathan S, Chandraker A,. Transplant tolerance through costimulation blockade-are we there yet? Front Biosci 2007; 12: 2935-2946.
4. Larsen CP, Elwood ET, Alexander DZ, et al,. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-438. (Pubitemid 26162734)
5. Lin H, Bolling SF, Linsley PS, et al,. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801-1806. (Pubitemid 23318461)
6. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
7. Durrbach A, Pestana JM, Pearson T, et al,. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557.
8. Brook MO, Wood KJ, Jones ND,. The impact of memory T cells on rejection and the induction of tolerance. Transplantation 2006; 82: 1-9. (Pubitemid 44296969)
9. Valujskikh A, Pantenburg B, Heeger PS,. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002; 2: 501-509. (Pubitemid 36306868)
10. Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW,. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: Therapeutic implications for sensitized transplant recipients. J Immunol 2002; 169: 4667-4673. (Pubitemid 35178248)
11. Croft M, Bradley LM, Swain SL,. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 1994; 152: 2675-2685.
12. Trambley J, Bingaman AW, Lin A, et al,. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999; 104: 1715-1722. (Pubitemid 30053188)
13. Augustine JJ, Siu DS, Clemente MJ, Schulak JA, Heeger PS, Hricik DE,. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5: 1971-1975. (Pubitemid 41039873)
14. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al,. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 2267-2275. (Pubitemid 29382237)
15. Poggio ED, Augustine JJ, Clemente M, et al,. Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 2007; 83: 847-852. (Pubitemid 46682724)
16. Adams AB, Williams MA, Jones TR, et al,. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887-1895. (Pubitemid 38057733)
17. Amir AL, D'Orsogna LJA, Roelen DL, et al,. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010; 115: 3146-3157.
18. Pribila JT, Quale AC, Mueller KL, Shimizu Y,. Integrins and T cell-mediated immunity. Annu Rev Immunol 2004; 22: 157-180. (Pubitemid 38680421)
19. Denucci CC, Mitchell JS, Shimizu Y,. Integrin function in T-cell homing to lymphoid and nonlymphoid sites: Getting there and staying there. Crit Rev Immunol 2009; 29: 87-109.
20. Evans R, Patzak I, Svensson L, et al,. Integrins in immunity. J Cell Sci 2009; 122 (Pt 2): 215-225.
21. Sims TN, Dustin ML,. The immunological synapse: Integrins take the stage. Immunol Rev 2002; 186: 100-117.
22. Langer HF, Chavakis T,. Leukocyte-endothelial interactions in inflammation. J Cell Mol Med 2009; 13: 1211-1220.
23. Rose DM, Alon R, Ginsberg MH,. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol Rev 2007; 218: 126-134. (Pubitemid 47052306)
24. Cox D, Brennan M, Moran N,. Integrins as therapeutic targets: Lessons and opportunities. Nat Rev Drug Discov 2010; 9: 804-820.
25. González-Amaro R, Mittelbrunn M, Sánchez-Madrid F,. Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: Two-edged swords? Immunology 2005; 116: 289-296. (Pubitemid 41532121)
26. Isobe M, Suzuki J, Yamazaki S, Sekiguchi M,. Acceptance of primary skin graft after treatment with anti-intercellular adhesion molecule-1 and anti-leukocyte function-associated antigen-1 monoclonal antibodies in mice. Transplantation 1996; 62: 411-413. (Pubitemid 26277351)
27. Grazia TJ, Gill RG, Gelhaus HC, Doan AN, Sleater ML, Pietra BA,. Perturbation of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 results in differential outcomes in cardiac versus islet allograft survival. J Heart Lung Transplant 2005; 24: 1410-1414. (Pubitemid 41247829)
28. Isobe M, Suzuki J, Yagita H, et al,. Immunosuppression to cardiac allografts and soluble antigens by anti-vascular cellular adhesion molecule-1 and anti-very late antigen-4 monoclonal antibodies. J Immunol 1994; 153: 5810-5818.
29. Paul LC, Davidoff A, Benediktsson H, Issekutz TB,. The efficacy of LFA-1 and VLA-4 antibody treatment in rat vascularized cardiac allograft rejection. Transplantation 1993; 55: 1196-1199. (Pubitemid 23150763)
30. Miwa S, Isobe M, Suzuki J, et al,. Effect of anti-intercellular adhesion molecule-1 and anti-leukocyte function associated antigen-1 monoclonal antibodies on rat-to-mouse cardiac xenograft rejection. Surgery 1997; 121: 681-689. (Pubitemid 27251908)
31. Arai K, Sunamura M, Wada Y, et al,. Preventing effect of anti-ICAM-1 and anti-LFA-1 monoclonal antibodies on murine islet allograft rejection. Int J Pancreatol 1999; 26: 23-31. (Pubitemid 29489582)
32. Nicolls MR, Coulombe M, Yang H, Bolwerk A, Gill RG,. Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4. J Immunol 2000; 164: 3627-3634. (Pubitemid 30169816)
33. Nishihara M, Gotoh M, Ohzato H, et al,. Awareness of donor alloantigens in antiadhesion therapy induces antigen-specific unresponsiveness to islet allografts. Transplantation 1997; 64: 965-970. (Pubitemid 27446759)
34. Stegall MD, Dean PG, Ninova D, et al,. alpha4 integrin in islet allograft rejection. Transplantation 2001; 71: 1549-1555. (Pubitemid 32574153)
35. Stegall MD, Ostrowska A, Haynes J, Karrer F, Kam I, Gill RG,. Prolongation of islet allograft survival with an antibody to vascular cell adhesion molecule 1. Surgery 1995; 118: 366-369; Discussion 369- 370.
36. Posselt AM, Bellin MD, Tavakol M, et al,. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant 2010; 10: 1870-1880.
37. Turgeon NA, Avila JG, Cano JA, et al,. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant 2010; 10: 2082-2091.
38. Badell IR, Russell MC, Thompson PW, et al,. LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Invest 2010; 120: 4520-4531.
39. Berney T, Pileggi A, Molano RD, et al,. The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. Transplantation 2003; 76: 1669-1674. (Pubitemid 38032411)
40. Corbascio M, Ekstrand H, Osterholm C, et al,. CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. Transpl Immunol 2002; 10: 55-61. (Pubitemid 34863326)
41. Malm H, Corbascio M, Osterholm C, et al,. CTLA4ig induces long-term graft survival of allogeneic skin grafts and totally inhibits T-cell proliferation in LFA-1-deficient mice. Transplantation 2002; 73: 293-297. (Pubitemid 34112856)
42. Nicolls MR, Coulombe M, Beilke J, Gelhaus HC, Gill RG,. CD4-dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways. J Immunol 2002; 169: 4831-4839. (Pubitemid 35217146)
43. Wang Y, Gao D, Lunsford KE, Frankel WL, Bumgardner GL,. Targeting LFA-1 synergizes with CD40/CD40L blockade for suppression of both CD4-dependent and CD8-dependent rejection. Am J Transplant 2003; 3: 1251-1258. (Pubitemid 37214621)
44. Ehst BD, Ingulli E, Jenkins MK,. Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. Am J Transplant 2003; 3: 1355-1362. (Pubitemid 37288079)
45. Dudani R, Chapdelaine Y, Faassen Hv Hv, et al,. Multiple mechanisms compensate to enhance tumor-protective CD8(+) T cell response in the long-term despite poor CD8(+) T cell priming initially: Comparison between an acute versus a chronic intracellular bacterium expressing a model antigen. J Immunol 2002; 168: 5737-5745. (Pubitemid 34556158)
46. Betts MR, Brenchley JM, Price DA, et al,. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65-78. (Pubitemid 37324571)
47. Barber DL, Wherry EJ, Ahmed R,. Cutting edge: Rapid in vivo killing by memory CD8 T cells. J Immunol 2003; 171: 27-31. (Pubitemid 36745269)
48. Wright KO, Murray DA, Crispe NI, Pierce RH,. Quantitative PCR for detection of the OT-1 transgene. BMC Immunol 2005; 6: 20.
49. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR,. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17-27. (Pubitemid 24035278)
50. Nicholson JK, Stein D, Mui T, Mack R, Hubbard M, Denny T,. Evaluation of a method for counting absolute numbers of cells with a flow cytometer. Clin Diagn Lab Immunol 1997; 4: 309-313. (Pubitemid 27239690)
51. Xie B, Chen J, Wang F, et al,. Monoclonal antibody treatment to prolong the secondary cardiac allograft survival in alloantigen-primed mice. Scand J Immunol 2010; 71: 345-352.
52. Zhang Q-W, Rabant M, Schenk A, Valujskikh A,. ICOS-dependent and -independent functions of memory CD4 T cells in allograft rejection. Am J Transplant 2008; 8: 497-506. (Pubitemid 351287530)
53. Floyd TL, Koehn BH, Kitchens WH, et al,. Limiting the amount and duration of antigen exposure during priming increases memory T cell requirement for costimulation during recall. J Immunol 2011; 186: 2033-2041.
54. Setoguchi K, Schenk AD, Ishii D, et al,. LFA-1 antagonism inhibits early infiltration of endogenous memory CD8 T cells into cardiac allografts and donor-reactive T cell priming. Am J Transplant 2011; 11: 923-935.
55. Oderup C, Malm H, Ekberg H, et al,. Costimulation blockade-induced cardiac allograft tolerance: Inhibition of T cell expansion and accumulation of intragraft cD4(+)Foxp3(+) T cells. Transplantation 2006; 82: 1493-1500. (Pubitemid 44967633)
56. Verbinnen B, Billiau AD, Vermeiren J, et al,. Contribution of regulatory T cells and effector T cell deletion in tolerance induction by costimulation blockade. J Immunol 2008; 181: 1034-1042.
57. Jiang XF, Cui ZM, Zhu L, et al,. CD40-CD40L costimulation blockade induced the tolerogenic dendritic cells in mouse cardiac transplant. Int Surg 2010; 95: 135-141.
58. Guillot C, Ménoret S, Guillonneau C, et al,. Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-term allograft survival by CTLA4Ig. Blood 2003; 101: 3325-3333. (Pubitemid 36858032)
59. El-Sawy T, Belperio JA, Strieter RM, Remick DG, Fairchild RL,. Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 2005; 112: 320-331. (Pubitemid 41022072)
60. Henderson RB, Lim LH, Tessier PA, et al,. The use of lymphocyte function-associated antigen (LFA)-1-deficient mice to determine the role of LFA-1, Mac-1, and alpha4 integrin in the inflammatory response of neutrophils. J Exp Med 2001; 194: 219-226. (Pubitemid 32673354)
61. Shen X, Reng F, Gao F, et al,. Alloimmune activation enhances innate tissue inflammation/injury in a mouse model of liver ischemia/reperfusion injury. Am J Transplant 2010; 10: 1729-1737.
62. Schenk AD, Nozaki T, Rabant M, Valujskikh A, Fairchild RL,. Donor-reactive CD8 memory T cells infiltrate cardiac allografts within 24-h posttransplant in naive recipients. Am J Transplant 2008; 8: 1652-1661.
63. Carson KR, Focosi D, Major EO, et al,. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816-824.
64. Clifford DB, De Luca A, Deluca A, et al,. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases. Lancet Neurol 2010; 9: 438-446.
65. Piccinni C, Sacripanti C, Poluzzi E, et al,. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur J Clin Pharmacol 2010; 66: 199-206.
66. Tyler KL,. Progressive multifocal leukoencephalopathy: Can we reduce risk in patients receiving biological immunomodulatory therapies? Ann Neurol 2010; 68: 271-274.